A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
Epistemonikos ID: a65f490148691cf12780b3c0e2b2ebd1b40f4054
First added on: May 05, 2024